GENEO Capital Entrepreneur
Also known as GENEO, GENEO Capital, GENEO Mezzanine, Geneo Capital Entrepreneur SAS
Paris manager (AMF GP-19000004) of the evergreen investment company GENEO Capital and GENEO Mezzanine; €1–40M equity and quasi-equity in profitable French and European SMEs and mid-caps.
- HEADQUARTERS
- Paris, France
- FOUNDED
- 2018
- AUM
- €750M (2026)
- OUTSIDE CAPITAL
- Yes
- TEAM LISTED
- 11 people
Focus
- STAGES
- GrowthBuyout
- SECTORS
- Industrial & ManufacturingHealthTechSoftware & SaaSConsumer & E-commerceFood & AgricultureFintech
- ASSET MIX
- Private equityPrivate credit
- GEOGRAPHY
- FranceEurope
Investment arms & vehicles
- Evergreen (99-year) investment company under the SCR tax regime, equity and convertible bonds in SMEs/mid-caps; managed by GENEO Capital Entrepreneur
- Quasi-equity (mezzanine) vehicle for mid-caps with an impact-indexed rate
Overview
GENEO Capital Entrepreneur is an independent AMF-authorised management company founded by Fanny Letier and François Rivolier and owned by its team. It manages GENEO Capital, a 99-year evergreen investment company backed by more than 280 entrepreneurs and families, and GENEO Mezzanine, a quasi-equity vehicle. It invests €1–40M in profitable SMEs and mid-caps with at least €5M revenue, in all sectors, for development, shareholder buy-outs and transmission, and reports more than €750M under management (June 2026).
Investment thesis
Long-term minority or reference investor in profitable French and European SMEs/mid-caps (min. €5M revenue, all sectors, strong CSR policy) for growth, acquisitions, minority buy-outs, management buy-outs and family transmission, using equity, convertible bonds and impact-indexed mezzanine.
PORTFOLIO (20)
- ChapsVisionNOTABLESoftware & SaaS
- TarkettNOTABLEIndustrial & Manufacturing
- EgisNOTABLEIndustrial & Manufacturing
- Leader GroupIndustrial & Manufacturing · since 2021
- DAPFintech · since 2025
- SeivenConsumer & E-commerce · since 2025
- MLabHealthTech · since 2025
- Pastacorp (Lustucru)Food & Agriculture · since 2025
- MyVariationsConsumer & E-commerce · since 2025
- DidacticHealthTech
- Neftys PharmaHealthTech
- XEFISoftware & SaaS
- OdigoSoftware & SaaS
- HoppenHealthTech
- SterimedHealthTech
- OTEGOIndustrial & Manufacturing
- MagilineConsumer & E-commerce
- EnygeaIndustrial & Manufacturing
- ValtusConsumer & E-commerce
- SAFIC ALCANIndustrial & Manufacturing
People
- Fanny LetierCo-founder · source
- François RivolierCo-founder · source
- Delphine JarnierAssociée (Partner) · source
- François PicarleAssocié (Partner) · source
- Marc DupuyAssocié (Partner) · source
- Stéphanie KordonianDirectrice associée · source
- Pierre-Olivier CombesDirecteur d’investissement · source
- Nicolas LapeyreDirecteur du Développement et de la Communauté · source
- Sabine Beaucamp-BousquiéSecrétaire Générale – Directrice financière · source
- Louis CharrierDirecteur de participations · source
- Marie KirchDirectrice de participations · source
Links
Frequently asked questions
GENEO Capital Entrepreneur is a private equity fund based in Paris, France, founded in 2018.
Yes. GENEO Capital Entrepreneur invests its own capital in private companies.
GENEO Capital Entrepreneur invests at Growth and Buyout stages in Industrial & Manufacturing, HealthTech, Software & SaaS, Consumer & E-commerce, Food & Agriculture and Fintech.
GENEO Capital Entrepreneur's stated ticket size is €1M–€40M.
Key people at GENEO Capital Entrepreneur include Fanny Letier (Co-founder), François Rivolier (Co-founder), Delphine Jarnier (Associée (Partner)) and François Picarle (Associé (Partner)).
GENEO Capital Entrepreneur's investments include ChapsVision, Tarkett, Egis, Leader Group, DAP, Seiven, MLab and Pastacorp (Lustucru), among others.
The most recent publicly reported investment by GENEO Capital Entrepreneur is Leader Group (Significant reinvestment alongside management and a co-investment vehicle of families and entrepreneurs, financing the acquisition of Mercedes Textiles (Canada)), announced in May 2026.
Yes. GENEO Capital Entrepreneur manages capital from outside investors.